4
Changes in Ownership
Dyne Therapeutics, Inc. Filed Acc 0000950170-24-008062
Chief Business Officer sold 20,000 shares at an average $24.53 ($490,510)
- Chief Business Officer acquired 20,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| McNeill Jonathan Chief Business Officer | 2024-01-26 | Option exercise 10b5-1 | +20,000 | $0.73 | $14,600 | 163,618 | D |
| McNeill Jonathan Chief Business Officer | 2024-01-26 | Sale 10b5-1 | −19,822 | $24.52 | $486,035 | 143,796 | D |
| McNeill Jonathan Chief Business Officer | 2024-01-26 | Sale 10b5-1 | −178 | $25.14 | $4,475 | 143,618 | D |
| Derivatives | |||||||
| McNeill Jonathan Chief Business Officer | 2024-01-26 | Option exercise · Stock option (right to buy) 10b5-1 | −20,000 | 28,528 | D | ||
| Open-market sales · 20,000 sh · avg $24.53 · $490,510 | |||||||
Loading xslF345X05/ownership.xml…